[
  {
    "ts": null,
    "headline": "Stock market today: Dow, S&P 500 slip as Trump stays firm on August tariff deadline, announces copper duties",
    "summary": "Investors are digesting Trump's stiff tariffs on imports from more than a dozen countries and delayed the return of sweeping April levies.",
    "url": "https://finnhub.io/api/news?id=12c0ac73d9cc5505678bbf10c23b364195435680ed971716860e125a792a1e4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752004893,
      "headline": "Stock market today: Dow, S&P 500 slip as Trump stays firm on August tariff deadline, announces copper duties",
      "id": 135819266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investors are digesting Trump's stiff tariffs on imports from more than a dozen countries and delayed the return of sweeping April levies.",
      "url": "https://finnhub.io/api/news?id=12c0ac73d9cc5505678bbf10c23b364195435680ed971716860e125a792a1e4c"
    }
  },
  {
    "ts": null,
    "headline": "Uber's highs, Trump tariff warning, Wendy’s CEO heads to Hershey",
    "summary": "Market Domination host Josh Lipton tracks key movers and headlines in this Market Minute. Pharma stocks such as Pfizer (PFE), Amgen (AMGN), and AbbVie (ABBV) are in focus after President Trump warned of tariffs up to 200%, though he hinted at a grace period for companies shifting production to the US. Uber (UBER) briefly hit another intraday record. Meanwhile, Wendy’s (WEN) CEO Kirk Tanner will exit the company to lead Hershey (HSY), with CFO Ken Cook stepping in as interim chief of the fast food chain. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=f06d83f3ce26c3a1771ddee70d6d411dd52da58d6f3c81a484d185c7865d8174",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751998666,
      "headline": "Uber's highs, Trump tariff warning, Wendy’s CEO heads to Hershey",
      "id": 135814702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Market Domination host Josh Lipton tracks key movers and headlines in this Market Minute. Pharma stocks such as Pfizer (PFE), Amgen (AMGN), and AbbVie (ABBV) are in focus after President Trump warned of tariffs up to 200%, though he hinted at a grace period for companies shifting production to the US. Uber (UBER) briefly hit another intraday record. Meanwhile, Wendy’s (WEN) CEO Kirk Tanner will exit the company to lead Hershey (HSY), with CFO Ken Cook stepping in as interim chief of the fast food chain. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=f06d83f3ce26c3a1771ddee70d6d411dd52da58d6f3c81a484d185c7865d8174"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=603bfb78b911a15cc23bc68a4af802102df555e635761aa59a8db67ecac27c6c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751992260,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 135858644,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=603bfb78b911a15cc23bc68a4af802102df555e635761aa59a8db67ecac27c6c"
    }
  },
  {
    "ts": null,
    "headline": "Nocturia Market Research and Forecast Report 2025-2034, Featuring Leading Players - Urigen Pharmaceuticals, Glenmark Pharmaceuticals, AbbVie, Teva Pharmaceuticals",
    "summary": "The nocturia market, valued at USD 3.30 Billion in 2024, is projected to reach USD 7.32 Billion by 2034, growing at an 8.30% CAGR. Factors driving growth include rising nocturia prevalence, especially among the aging population, technological advancements, and innovative treatments. Key players include Urigen Pharmaceuticals, Glenmark, and AbbVie. Nocturia Market Nocturia Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The \"Nocturia Market Report and Forecast 2025-2034\" has been added to Resear",
    "url": "https://finnhub.io/api/news?id=8274d9fddbb8c37be8c8fe72808b1685079998c5570329ef0d9303369287d921",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751980500,
      "headline": "Nocturia Market Research and Forecast Report 2025-2034, Featuring Leading Players - Urigen Pharmaceuticals, Glenmark Pharmaceuticals, AbbVie, Teva Pharmaceuticals",
      "id": 135805794,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The nocturia market, valued at USD 3.30 Billion in 2024, is projected to reach USD 7.32 Billion by 2034, growing at an 8.30% CAGR. Factors driving growth include rising nocturia prevalence, especially among the aging population, technological advancements, and innovative treatments. Key players include Urigen Pharmaceuticals, Glenmark, and AbbVie. Nocturia Market Nocturia Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The \"Nocturia Market Report and Forecast 2025-2034\" has been added to Resear",
      "url": "https://finnhub.io/api/news?id=8274d9fddbb8c37be8c8fe72808b1685079998c5570329ef0d9303369287d921"
    }
  },
  {
    "ts": null,
    "headline": "How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?",
    "summary": "ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.",
    "url": "https://finnhub.io/api/news?id=a18c12cd77ddee6772eeda08f133bcb8c233bd69bdcc839a042f8df8b92a629b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751977620,
      "headline": "How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?",
      "id": 135805660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.",
      "url": "https://finnhub.io/api/news?id=a18c12cd77ddee6772eeda08f133bcb8c233bd69bdcc839a042f8df8b92a629b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune Pipeline",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition will expand AbbVie’s product pipeline, particularly in experimental treatments for autoimmune diseases. Capstan Therapeutics […]",
    "url": "https://finnhub.io/api/news?id=1fa7553980659158be8f046763ef75e2a15b0a95c5ab03f8df00ccd99e6fdabd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751967134,
      "headline": "AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune Pipeline",
      "id": 135805796,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition will expand AbbVie’s product pipeline, particularly in experimental treatments for autoimmune diseases. Capstan Therapeutics […]",
      "url": "https://finnhub.io/api/news?id=1fa7553980659158be8f046763ef75e2a15b0a95c5ab03f8df00ccd99e6fdabd"
    }
  },
  {
    "ts": null,
    "headline": "Is biopharma dealmaking getting hot again?",
    "summary": "With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.",
    "url": "https://finnhub.io/api/news?id=8eb2fc3456089b7eb23597daeb3486f6a7101fe81aa22a3bafcd87f80f47fd53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751961600,
      "headline": "Is biopharma dealmaking getting hot again?",
      "id": 135805797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.",
      "url": "https://finnhub.io/api/news?id=8eb2fc3456089b7eb23597daeb3486f6a7101fe81aa22a3bafcd87f80f47fd53"
    }
  }
]